about
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life OutcomesLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsInvasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literatureCIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patientsUpregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphomaLiquid chromatographic determination of urinary 5-methyl-2'-deoxycytidine and pseudouridine as potential biological markers for leukaemiaMutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia.The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).Dasatinib first-line: Multicentric Italian experience outside clinical trials.Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseAquaporin-4 expression in primary human central nervous system lymphomas correlates with tumour cell proliferation and phenotypic heterogeneity of the vessel wall.FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians.Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patientsConcomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature.High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia.Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyAutoimmune myelofibrosis: report of three cases and review of the literature.Acute lymphoblastic leukemia hand-mirror cells. Study of nine cases.The role of angiogenesis in human non-Hodgkin lymphomas.Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature.Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsSIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsCurrent management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.
P50
Q23671265-919B830D-5D75-4A3B-87FE-1809BFE53CB4Q26849243-D7293EB3-8848-4179-A1F8-4A5F18129B8AQ28243864-0933BC34-CC47-4813-8725-EF7F4656A219Q28259307-5773833D-E048-4276-81C1-F3D77F4B0FAAQ28305360-2A3D6796-BD53-414E-86C9-2A9FCBDB80FFQ28372362-D6E981C5-7F1C-4EDD-8CAE-8455E7232DB4Q33254865-516E2CF3-9079-4F7C-9E9C-122B9A6E43DAQ33385124-FEB3EA52-D2F7-4C11-B256-7B74EEEFC630Q33409020-5446BC11-73F4-4DE3-B639-6F7AA1A43D8BQ33419053-8AA5FAF0-C4E5-46DA-AEAF-4FA4661A0755Q33423295-A648C102-EB2A-48E0-8DC1-DD113584DAAFQ33427785-A77A4792-0317-4E8F-A4A6-CAC6710679CEQ33428221-2F62A297-B3D6-4C9D-A4A1-717970166E6DQ33919931-D91F748B-DEAE-47B9-B441-62BB9D58A565Q34032263-2D616704-2502-473B-96AD-07C5CCA22D1EQ34078856-D8E7DAC0-0154-4CBD-A5CC-CB46268860A0Q34192067-D7BD2518-8E0E-4327-9CF0-2ADF9CDFA25DQ34225646-6C6D6771-2219-4EB7-8FA1-6A71D0CC2070Q34501005-767FD9A6-7746-48F7-A860-B7AECC860843Q34621685-EB5BD077-74E9-47B9-BFEE-1089F791E7D5Q34890434-D9C69B26-50D1-4F89-A5E7-7AC6AC795E67Q34984670-9395846C-A704-4B75-B302-9C4E6DDB3436Q35047638-F4062D5B-B510-4A82-A186-BCDDCB37D530Q35057869-09BBBB40-DD8E-4919-9DD7-61AA3242293CQ35265868-4B73960E-F8D5-47BA-87B8-539EFFC3C62EQ35433005-8C08605B-CF17-47C4-B45D-6510A078D3F3Q35525365-6BF7E78E-DF92-4E0E-AD80-443DA2DF15A4Q35636700-611831DC-4B69-4A7F-B0A1-083687ECB284Q35782545-044E42FC-3A62-4318-A46D-56CB8176CD21Q36615025-EF1298A3-8A38-4636-86D6-8AA546AA58ACQ36670881-5F3FCB16-0556-4846-951D-C88E69D93064Q36715906-78FD5678-5D5E-421B-8F45-3C873F1F0A90Q36862301-A155123B-C43A-4E9E-9060-BD0D6E759D1FQ37082725-047DDE01-9E77-472B-AA1D-417A46D7450EQ37156515-74D9AA06-9F14-4DE6-80D2-53B601387637Q37273171-AF07C625-4A32-4B58-844A-AB28BEF23A55Q37530914-8976CCE0-6C4B-4A8E-9537-8E33A2A5D2D2Q37903768-DB083976-9CF0-40EB-85CF-27D6DE3232B9Q38134374-84D1D19E-BF1A-48C7-A8BF-1F7777651253Q38177029-8CC3E02A-0905-43FC-8857-482C731BB861
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giorgina Specchia
@ast
Giorgina Specchia
@en
Giorgina Specchia
@es
Giorgina Specchia
@nl
Giorgina Specchia
@sl
type
label
Giorgina Specchia
@ast
Giorgina Specchia
@en
Giorgina Specchia
@es
Giorgina Specchia
@nl
Giorgina Specchia
@sl
prefLabel
Giorgina Specchia
@ast
Giorgina Specchia
@en
Giorgina Specchia
@es
Giorgina Specchia
@nl
Giorgina Specchia
@sl
P1053
K-3084-2016
P106
P1153
55141985600
P21
P31
P3829
P496
0000-0002-2479-9529